Preparation and Evaluation of 2-(Allylthio)Pyrazine-Loaded Lipid Emulsion with Enhanced Stability and Liver Targeting

References

• P. P. Constantinides, S. H. Yiv. 1995. Particle size determination of phase-inverted water-in-oil microemulsions under different dilution and storage conditions. Int. J. Pharm. 115:225–234.
   Web of Science ®Google Scholar
• S. Costa, A. Utan, E. Speroni, R. Cervellati, G. Piva, A. Prandini, M. C. Guerra. 2007. Carnosic acid from rosemary extracts: A potential chemoprotective agent against aflatoxin B1. An in vitro study. J. App. Toxicol. 27 (2):152–159.
   PubMed Web of Science ®Google Scholar
• D. F. Driscoll. 2006. Lipid injectable emulsions: Pharmacopeial and safety issues. Pharm. Res. 23 (9):1959–1969.
   PubMed Web of Science ®Google Scholar
• A. G. Floyd. 1999. Top ten considerations in the development of parenteral emulsions. Pharm. Sci. Technol. Today 4 (2):134–143.
   PubMedGoogle Scholar
• M. Gibaldi, D. Perrier. 1982. Pharmacokinetics (2nd ed. ). New York: Marcel-Dekker.
   Google Scholar
• R. N. Gursoy, S. Benita. 2004. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed. Pharmacother. 58 (3):173–182.
   PubMed Web of Science ®Google Scholar
• T. G. Ha, N. D. Kim. 1998. 2-AP inhibition of aflatoxin B1-induced hepatoxocity and its covalent DNA binding in rats by inhibition of cytochrome P450 2B and 3A2. Res. Commun. Mol. Path. Pharmacol. 102:69–78.
   PubMed Web of Science ®Google Scholar
• K. S. Han, M. G. Lee. 1999. Pharmacokinetics of chemopreventive agent, 2-(allylthio)pyrazine, after intravenous and oral administration to rats: Hepatic and gastric first pass effects. Drug Metab. Dispos. 27:221–226.
   PubMed Web of Science ®Google Scholar
• T. G. Ha, J. J. Jang, S. G. Kim, N. D. Kim. 1999. 2-(Allylthio) pyrazine inhibition of afatoxin B1-induced hepatocarcinogenesis in rats. Chem. Bio. Interact. 121:209–222.
   PubMed Web of Science ®Google Scholar
• S. R. Hwang, S. J. Lim, J. S. Park, C. K. Kim. 2004. Phospholipid-based microemulsion formulation of all-trans-retinoic acid for parenteral administration. Int. J. Pharm. 276 (1–2):175–183.
   PubMed Web of Science ®Google Scholar
• K. W. Kang, J. R. Ha, C. W. Kim, N. D. Kim, S. G. Kim. 2001. 2-(Allylthio)pyrazine, a cancer chemopreventive agent, inhibits liver fibrosis induced by dimethylnitrosamine in rats: Role of inhibition of transforming growth factor-β1 expression. Pharmacol. Toxicol. 89:23–29.
   PubMedGoogle Scholar
• N. D. Kim, S. G. Kim, M. K. Kwak. 1994. Enhanced expression of rat microsomal epoxide hydrolase gene by organosulfur compounds. Biochem. Pharmacol. 47:541–547.
   PubMed Web of Science ®Google Scholar
• Y. G. Kim, M. K. Cho, J. W. Kwon, D. H. Kim, S. G. Kim, M. G Lee. 1997. Effects of cysteine on the pharmacokinetics of intravenous 2-(allylthio) pyrazine, a new chemoprotective agent, in rats with protein-calorie malnutrition. Int. J. Pharm. 225:1–11.
   Google Scholar
• N. D. Kim, M. K. Kwak, S. G. Kim. 1999. Inhibition of cytochrome P450 2E1 expression by 2-(allylthio) pyrazine, a potential chemoprotective agent: Hepatoprotective effects. Biochem. Pharmacol. 53:261–269.
   Web of Science ®Google Scholar
• M. K. Kwak, W. I. Lee, N. D. Kim, M. G. Lee. 1998. Metabolic changes of acetaminophen after intravenous administration to rats pretreated with 2-(allylthio)pyrazine. Biopharm. Drug Dispos. 19:273–277.
   PubMed Web of Science ®Google Scholar
• A. M. Laval-Jeantet, M. Laval-Jeantet, C. Bergot. 1982. Effects of particle size on the tissue distribution of iodized emulsified fat following intravenous administration. Invest. Radiol. 17:617–620.
   PubMed Web of Science ®Google Scholar
• E. J. Lee, E. J. Kim, Y. G. Kim, H. C. Chung, S. H. Kim, D. H. Kim, I. Lees, S. G. Kim, M. G. Lee. 2004. Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of 2-(allylthio) pyrazine, a chemoprotective agent, in rats: The role of CYP3A23 induction. Res. Commun. Mol. Pathol. Pharmacol. 115–116.111–121.
   Google Scholar
• D. Liu, A. Mori, L. Huang. 1992. Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes. Biochem. Biophys. Acta 1104:95–101.
   PubMed Web of Science ®Google Scholar
• X. Sha, G. Yan, J. Li, X. Fang. 2005. Effect of self microemulsifying drug delivery systems containing Labrasol on tight junction in Caco-2 cells. Eur. J. Pharm. Sci. 24 (5):477–486.
   PubMed Web of Science ®Google Scholar
• Society of Toxicology (SOT). 1999. Guilding principles in the use of animals in toxicology, Available from www.toxicology.org/AI/FA/guidingprinciples.pdf.
   Google Scholar
• Y. J. Surh, S. G. Kim, K. K. Park, Y. W. Sohn, J. M. Lee, N. D. Kim, J. A. Miller. 1998. Chemopreventive effects of 2-(allylthio)pyrazine on hepatic lesion, mutagenesis, and tumorigenesis induced by vinyl carbamate or vinylcarbamate epoxide. Carcinogenesis 19:3263–3267.
   Web of Science ®Google Scholar
• S. Tamilvanan. 2004. Oil-in-water lipid emulsions: Implications for parenteral and ocular delivering systems. Prog. Lipid Res. 43:489–533.
   PubMed Web of Science ®Google Scholar
• C. C. Von, P. Thoren, S. Engstrom. 1998. Triglyceride-based microemulsion for intraveous administration of sparingly soluble substances. J. Pharm. Sci. 87:200–208.
   PubMed Web of Science ®Google Scholar
• Y. G. Yim, M. K. Cho, J. W. Kwon, D. H. Kim, S. G. Kim, M. G. Lee. 2003. Effects of cysteine on the pharmacokinetics of intravenous 2-(allylthio)pyrazine, a new chemoprotective agent, in rats with protein-calorie malnutrition. Int. J. Pharm. 255 (1–2):1–11.
   PubMedGoogle Scholar
• C. S. Yong, C. H. Yang, J. D. Rhee, B. J. Lee, D. C. Kim, D. D. Kim, C. K. Kim, J. S. Choi, H. G. Choi. 2004. Enhanced rectal bioavailability of ibuprofen in rats by poloxamer 188 and menthol. Int. J. Pharm. 269:169–176.
   PubMed Web of Science ®Google Scholar